



New Approaches in Vaccine Development for the Control of Vectors and Vector-Borne Diseases

Guest Editors:

Dr. Marinela Contreras

SaBio, Instituto de Investigación en Recursos Cinegéticos IREC-CSIC-UCLM-JCCM, Ciudad Real, Spain

Dr. Sara Artigas Jerónimo

SaBio, Instituto de Investigación en Recursos Cinegéticos IREC-CSIC-UCLM-JCCM, Ciudad Real, Spain

Deadline for manuscript submissions:

closed (30 September 2023)

Message from the Guest Editors

Dear Colleagues,

Vaccination is an environmentally friendly alternative for the control of emerging vector-borne and infectious diseases. One of the main limitations in the development of effective vaccines for the prevention and control of vector infestation and pathogen transmission is the identification and design of effective protective antigens. Therefore, new challenges such as host immunity, pathogen and environmental factors, vaccine efficacy and safety need to be addressed.

This Special Issue aims to include the latest approaches that are being used for the identification and characterization of new vaccine antigen candidates. Potential topics include mosquitoes, ticks, mites, sandflies, malaria, Lyme diseases, anaplasmosis, Crimean–Congo virus, and flaviviruses. Topics related to vector vaccine development, vaccination and vaccine safety are also included. If you need a voucher or waiver, please contact <vaccines@mdpi.com>.

Dr. Marinela Contreras
Dr. Sara Artigas Jerónimo
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com